Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development - Wikidata - awgldk - TriplyDB

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development

http://www.wikidata.org/entity/Q27643965

about

Chemical Variations on the p53 Reactivation Theme Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics Molecular docking and structure-based drug design strategies 8-Triazolylpurines: Towards Fluorescent Inhibitors of the MDM2/p53 Interaction Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex.Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism Genomic Classification of Cutaneous Melanoma Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.Small-molecule MDM2-p53 inhibitors: recent advances.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?New Frontiers in Druggability How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors.AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein-Protein Interaction Interfaces.Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 Potential Therapeutic Targets in Uterine Sarcomas.The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers.Radiosensitization of adenoid cystic carcinoma with MDM2 inhibition.Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.Identifying the determinants of response to MDM2 inhibition.Microsecond simulations of mdm2 and its complex with p53 yield insight into force field accuracy and conformational dynamics.MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways.Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.Reviving the guardian of the genome: Small molecule activators of p53.Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation.The Role of MDM2 in Promoting Genome Stability versus Instability.Virtual screening for inhibitors of the human TSLP:TSLPR interaction.A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.Understanding Protein-Protein Interactions: Essential Players in (Patho)physiology (Part 1).The Roles of MDM2 and MDMX in Cancer.Reductive Transformations of Carbonyl Compounds Catalyzed by Rhodium Supported on a Carbon Matrix by using Carbon Monoxide as a Deoxygenative Agent Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

P2860

Q26749008-BC003569-6F6D-4905-8B5C-7CA04ED364BD Q26775356-775CAB9A-AFFF-465F-B498-FDF9077BB1BC Q26800097-FAF7EB27-5A86-4F5F-B06F-9B3CB008FFAF Q28547009-FB8F31CC-AAFF-43B1-91FD-4A4EADF105EA Q28548694-369518F8-DFE1-48E2-8BF8-A3A31D0E8D4E Q30176404-699D60C2-B8F5-4675-9FB7-F671C250ED6C Q33572704-18252595-B614-4330-ABDC-C79A805FD822 Q33869257-65AB2CBD-278B-460D-8AEA-579CD57B39B3 Q34063712-D6787E5E-0BDD-4C69-80EC-862BD27B445E Q34079481-BE02D46C-C74E-40D4-A97A-BCE5F86F1474 Q34670776-9CD4E2B9-CFDE-468F-8641-BC2ADAF23824 Q35087851-1732ECBB-7AFB-42B7-9805-752D62863725 Q35550054-8EACCF6C-229B-4B48-9650-87EE2C88A148 Q35617077-B1343438-A8A4-430F-AA06-D70439A20E0C Q35687836-474D5C1A-6674-48FC-ABAB-B8C08B49A380 Q35730955-24809114-7D01-45EB-B9B3-2EE8D55574A8 Q35871210-1C3F0C4D-0986-4E4B-845D-BC9A43A26DC7 Q35874377-ACF8F6E5-EA32-4858-9410-288F36DC640E Q35935872-56852EF3-540F-4456-A102-07298FD284E6 Q35997296-A7C88F97-8485-4825-90CC-9E3765C7D77B Q36132787-7EE522EE-0A39-4D7B-8830-D7ABF59F0470 Q36245677-0902C116-9FCB-4B2E-AE3B-94149FDA8D69 Q38637803-57831F55-E778-4E86-8CEF-2421A9306987 Q38703939-4EE97796-2B0A-4DCD-ABED-3A928E87F067 Q38749151-3F040E73-157C-429A-9120-1AE896ABD6B6 Q38767574-00860257-DEAE-4D63-95EB-254B2B975CD6 Q38865504-8F679116-3575-416F-A26D-4020CE84BE40 Q38904655-6F0A1EF4-8472-4BA3-9858-B713486479C4 Q38988816-0E30D90F-24D6-462D-9C89-4BDF4E7FE52B Q38997002-B016BA9D-B3A7-45BA-B7B2-E77785D4A6A6 Q39036213-D9A7FE99-634B-4B08-B6EC-D39F0BACE48D Q39205536-95A53334-EA3D-40E6-9895-EF66877E21DC Q41179373-5020D88D-7210-4C66-9890-1A1E73329D76 Q47096280-5BB0B7F7-C855-4F41-9A84-B3FD03C2C9D1 Q47133599-1B20F4FF-4D12-46A2-8EFE-55167656A42A Q47152365-59C531FB-195C-46F2-AB58-601B84A9F92F Q52817076-21FFCA49-8462-44C0-A260-E1507A7F2882 Q55517350-01EF3125-C66F-40AD-9814-2531385CF85C Q57998768-2E10BFAA-1B9D-4B1B-B96E-73E8D2B8964A Q58697064-FC467053-DFEB-4B09-B426-534F2122E491

P2860

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development

http://www.wikidata.org/entity/Q27643965

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Discovery of AMG 232, a potent ...... ibitor in clinical development

@ast

Discovery of AMG 232, a potent ...... ibitor in clinical development

@en

Discovery of AMG 232, a potent ...... ibitor in clinical development

@nl

type

label

Discovery of AMG 232, a potent ...... ibitor in clinical development

@ast

Discovery of AMG 232, a potent ...... ibitor in clinical development

@en

Discovery of AMG 232, a potent ...... ibitor in clinical development

@nl

prefLabel

Discovery of AMG 232, a potent ...... ibitor in clinical development

@ast

Discovery of AMG 232, a potent ...... ibitor in clinical development

@en

Discovery of AMG 232, a potent ...... ibitor in clinical development

@nl

P1433

Q27643965-1B867506-2435-4A0F-B09D-DE3B72FD0432

P1476

Q27643965-FC46C2C1-AEB6-4A7E-99B1-D08A98C49DF1

P2093

Q27643965-0A9C2D15-002F-45C9-B5B2-8C8C610B8673

Q27643965-126ECE7E-7277-425E-8DF5-7CE855F94D04

Q27643965-2B5E182D-75C9-4244-BF52-287E841B4F0F

Q27643965-2E1549E7-2952-458C-9CFD-04BFDEB614B7

Q27643965-300471EE-E4D5-4849-BB7C-81E3494814E3

Q27643965-34376747-8718-485C-8665-A49CD39E800F

Q27643965-34D97120-6750-4382-A522-177EB4DF2E48

Q27643965-35359F7F-E658-4FD7-8FB1-88403149E246

Q27643965-39A183A9-7EEB-47AE-B27A-B46B09F11141

Q27643965-3D2768BA-4F74-4FD6-8434-D991521812C2

P304

Q27643965-1E8C2EF6-D154-4FEA-B410-2255CE4CEC83

P31

Q27643965-6E416927-C2C5-45B5-9C89-E255C2AED092

P3181

Q27643965-230474C5-4AEA-444E-A6B6-B107C7D28398

P356

Q27643965-1686FDDB-C8C6-414C-B5B8-9CF94D68A3A8

P407

Q27643965-F6A0C0CD-3DFE-4D63-9E6F-74860F95A2DD

P433

Q27643965-33F3C3A6-5234-4991-A010-EABD7B292813

P478

Q27643965-DF9C56B3-B336-4AC0-88AF-4AD52FFD9A63

P50

Q27643965-07B2DFC7-F15F-407F-896C-77B1706D63E0

P577

Q27643965-3FE638A1-6142-4320-B586-1903B7173C3D

P5875

Q27643965-24811E94-646F-45C4-875C-47EC0CD6D639

P698

Q27643965-36B61BFA-36EA-48B3-98D9-6593816B1253

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of AMG 232, a potent ...... ibitor in clinical development

@en

P2093

Ada Chen

http://www.w3.org/2001/XMLSchema#string

Alexander M Long

http://www.w3.org/2001/XMLSchema#string

Ana Z Gonzalez

http://www.w3.org/2001/XMLSchema#string

Benjamin Fisher

http://www.w3.org/2001/XMLSchema#string

Brian Lucas

http://www.w3.org/2001/XMLSchema#string

Brian M Fox

http://www.w3.org/2001/XMLSchema#string

Daqing Sun

http://www.w3.org/2001/XMLSchema#string

David Chow

http://www.w3.org/2001/XMLSchema#string

Dongyin Yu

http://www.w3.org/2001/XMLSchema#string

Felix Gonzalez-Lopez De Turiso

http://www.w3.org/2001/XMLSchema#string

P304

1454-1472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1648274

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM401753E

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259881034

http://www.w3.org/2001/XMLSchema#string

P698

24456472

http://www.w3.org/2001/XMLSchema#string